JMP Securities raised the firm’s price target on Benitec Biopharma to $16 from $10 and keeps an Outperform rating on the shares. Results with BB-301 in a first oculopharyngeal muscular dystrophy patient showed significant improvements versus patient history across functional, physiological, and patient-reported outcomes, the analyst tells investors in a research note. The firm increased its BB-301 probability of success to 45% from 30% following the data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma’s $40 Million Equity Financing Deal
- Benitec Biopharma Showcases Encouraging Clinical Trial Results
- Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
- Benitec Biopharma reports interim trial data for subject treasted with BB-301
- Benitec Biopharma announces $40M oversubscribed private placement financing
